Ribbon signs DRC Medicine deal, extends deadline to Jan 2027 amid liquidity crunch

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~1 min read

Key Changes

• high

  Company entered definitive merger agreement with DRC Medicine on June 30, 2025, ending search phase. Deal values target at $350M divided by redemption price per share, determining dilution to existing holders.

  MD&A: Business Combination Agreement verify on EDGAR →
• high

  Shareholders approved 12-month extension to January 2027 requiring $125K monthly trust deposits. Nearly 1.44M shares (29% of IPO) redeemed at the vote, reducing available cash and increasing dilution.

  MD&A: Extension and Redemptions verify on EDGAR →
• high

  Working capital swung from $516K surplus to $1.0M deficit year-over-year. Company borrowed $600K from sponsor in March 2026 to fund operations, signaling exhausted cash reserves outside trust.

  MD&A: Working Capital verify on EDGAR →